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Abstract
Background: Endothelial progenitor cell (EPC) transplantation is a promising therapy for ischemic diseases such as
ischemic myocardial infarction and hindlimb ischemia. However, limitation of EPC sources remains a major obstacle.
Direct reprogramming has become a powerful tool to produce EPCs from fibroblasts. Some recent efforts successfully
directly reprogrammed human fibroblasts into functional EPCs; however, the procedure efficacy was low. This study
therefore aimed to improve the efficacy of direct reprogramming of human fibroblasts to functional EPCs.
Methods: Human fibroblasts isolated from foreskin were directly reprogrammed into EPCs by viral ETV2 transduction.
Reprogramming efficacy was improved by culturing transduced fibroblasts in hypoxia conditions (5 % oxygen).
Phenotype analyses confirmed that single-factor ETV2 transduction successfully reprogrammed dermal fibroblasts
into functional EPCs.
Results: Hypoxia treatment during the reprogramming procedure increased the efficacy of reprogramming from
1.21 ± 0.61 % in normoxia conditions to 7.52 ± 2.31 % in hypoxia conditions. Induced EPCs in hypoxia conditions
exhibited functional EPC phenotypes similar to those in normoxia conditions, such as expression of CD31 and
VEGFR2, and expressed endothelial gene profiles similar to human umbilical vascular endothelial cells. These cells
also formed capillary-like networks in vitro.
Conclusion: Our study demonstrates a new simple method to increase the reprogramming efficacy of human
fibroblasts to EPCs using ETV2 and hypoxia.
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Background
Endothelial progenitor cells (EPCs) trigger angiogenesis
and vasculogenesis, and thus have been used in the
treatment of diseases related to ischemia. EPCs have
been isolated from peripheral blood [1–5], bone marrow
[6–8], and umbilical cord blood [9–12]. Several studies
have demonstrated successful preclinical application of
EPCs in various disease models, such as rat myocardial
infarction [13–15], murine hindlimb ischemia [16], rat
ischemic myocardium [17], dermal wound healing [18],
and mouse ovarian grafts [19]. A recent study showed
that EPC transplantation could increase neovasculariza-
tion in porcine models [20]. Clinically, EPC transplant-
ation can improve cardiovascular outcomes. In a phase
I/II clinical trial of 24 patients [21] followed by a phase
IIb trial with 167 patients [22], almost all patients sub-
jected to EPC transplantation showed improved angina
frequency and exercise tolerance. In another phase III
trial of 444 patients, CD34 cell transplantation could im-
prove the functional capacity in patients with refractory
angina [23]. In addition to coronary artery diseases,
other pilot studies have also used autologous CD34 to
treat critical limb ischemia and showed reduced
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amputation rates in critical limb ischemic patients [24].
Several studies have also genetically modified EPCs by
transfecting cells with genes to increase the treatment
efficacy, such as hTERT-transfected EPCs for ischemic
myocardium of rats [25], vascular endothelial growth
factor (VEGF)-transfected EPCs for myocardial infarc-
tion [26], and VEGF and heme oxygenase-1-transfected
EPCs for the hindlimb ischemia mice model [27, 28].
Human cord blood endothelial progenitors could also
promote postischemic angiogenesis in an immunocom-
petent mouse model [29].
Successful application of EPC treatments in the clinic,
however, has encountered several obstacles, such as lim-
ited EPC sources, low numbers of cells, and low prolifer-
ation. The number of EPCs in peripheral blood and
bone marrow is extremely low [5, 30]. Therefore, deriv-
ing endothelial cells as well as EPCs from pluripotent
stem cells was studied [31–33]. Although EPCs derived
from embryonic stem cells were suggested to be a more
promising therapy compared with umbilical cord EPCs
[34], this application has not been translated to the clinic
owing to the risk of pluripotent stem cells stimulating
tumor formation [35, 36]. Current research has thus fo-
cused on human fibroblasts (HFs) as a cell source for re-
programming to EPCs.
The first effort towards direct reprogramming of fibro-
blasts to EPCs was performed by Margariti et al. [37].
The authors developed a method to generate partial-
induced pluripotent stem cells by transferring four re-
programming factors (OCT4, SOX2, KLF4, and c-MYC)
to HFs for 4 days. These partial-induced pluripotent
stem cells were capable of differentiating into endothelial
cells in response to defined media and culture condi-
tions [37]. However, although the endothelial cells ob-
tained could not form tumors, these cells carried
oncogenes such as Sox-2 [37]. Li et al. and Han et al.
successfully removed the Sox-2 gene in a revised version
of the procedure and instead only used two genes (Oct4
and Klf4) in combination with soluble factors [38] or
Foxo1, Er71, Klf2, Tal1, and Lmo2 [39]. These studies
used a mixture of factors to induce fibroblasts to EPCs
and involved complex procedures with low efficacy.
Recently, ETV2 was reported as a single factor that
could induce direct reprogramming of fibroblasts into
EPCs [40, 41] and of amniotic cells into EPCs [42]. In
fact, ETV2 is a master gene that regulates various signal-
ing pathways and functions as an essential regulator for
vasculogenesis and hematopoiesis. ETV2 and GATA2
bind to the promoter of SPI1 and regulate its expression
during embryogenesis [43]. ETV2 regulates cardiac de-
velopment [44], and vascular regeneration [45]. How-
ever, the direct reprogramming of ETV2 transduction
was low (about 1 %) [41]. Several studies have reported
that hypoxia could improve reprogramming of cells. Foja
et al. [46] showed that hypoxia improved the reprogram-
ming of MSCs into induced pluripotent stem cells
(iPSCs). Adipose stem cells were also stimulated for re-
programming to iPSCs by hypoxia [47]. Hypoxia also en-
hanced the reprogramming of fibroblasts into iPSCs [48]
and dental pulp cells into iPSCs [49]. This study
therefore examined the potential enhancement of direct
reprogramming efficacy to EPCs by single-factor ETV2
under hypoxia treatment.
Methods
Isolation and culture of human dermal fibroblasts and cell
culture
Foreskin was collected from a donor who provided a
consent form at the hospital. Foreskin was stored in PBS
solution at 4 °C and transferred to the laboratory for iso-
lation and culture of fibroblasts, as described in previous
studies [50]. Briefly, the samples were cut into small
pieces, placed into wells, and allowed to adhere for
5 min at room temperature. DMEM medium supple-
mented with 10 % FBS, 1× anti-mitotic-mycotic was
then added to the wells and the cultures were main-
tained at 37 °C, 5 % CO2. The cultures were subcultured
when cells reached 70–80 % confluence. HFs were con-
tinuously subcultured to third passages and these cells
were used in further experiments. Human umbilical vein
endothelial cells (HUVECs) were purchased from Life-
technologies (code number C0035C; Carlsbad, CA, USA).
Lentivirus production
The human ETV2 expression vector (pF1KB9707) was
purchased from Addgene (Cambridge, MA, USA). ETV2
was cloned into the vector backbone pSIN4-EF1alpha-
IRES-Puro (Plasmid #61061; Addgene, Cambridge, MA,
USA) to generate pSIN4-EF1a-ETV2-IRES-Puro. All of
the coding sequences in the expression vector were con-
firmed with a GenomeLab System (Beckman Coulter,
Brea, CA, USA). The ETV2 vector was then transfected
into HEK293T cells along with pCMV-VSV-G-RSV-Rev
and pCMV-dR8.2 (Addgene). Eighteen hours after trans-
fection, the medium was replaced with fresh culture
medium, and 48 h later the lentivirus-containing medium
was collected, passed through a 0.45-μm filter, and concen-
trated using centrifugation (8400 × g at 4 °C for 16 h). The
lentivirus pellets were resuspended in PBS at 107 IFUs/ml.
ETV2 transduction of cells
HFs were plated on 12-well plates at 7 × 104 cells per
well and 24 h later were infected with the 10 μl concen-
trated lentivirus particles with 5 μg/ml protamine. Plates
were grouped into two groups: normoxia and hypoxia.
The normoxia group was incubated in 20 % O2, 5 %
CO2, 37 °C, while the hypoxia group was incubated in
5 % O2, 5 % CO2, 37 °C. Another 48 h later, cells were
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washed twice with PBS and then cultured on 6-cm
dishes coated with Cellstart (Lifetechnologies) in EGM-2
medium under normoxia or hypoxia conditions.
VEGF treatment
Anti-VEGF monoclonal antibody was added into the
medium at 10 ng/ml before culturing cells under hyp-
oxia conditions. The medium was replaced after 3 days
with medium containing an anti-VEGF antibody (P931;
Lifetechnologies). In the normoxia group, recombinant
protein VEGF at 10 ng/ml was added into the culture
medium. The medium was replaced for 3 days with fresh
medium containing recombinant VEGF. Cells were then
infected with ETV2 virus. After 21 days, the samples
were subjected to experimental analyses.
Quantitative RT-PCR
Total RNA was extracted using Trizol according to the
manufacturer’s instructions. PCR analysis was per-
formed using one-step real-time RT-PCR and the SYBR®
Green Quantitative RT-qPCR Kit (Sigma-Aldrich, St.
Louis, MO, USA) on a Realplex Mastercycler (Eppendorf).
Relative gene expression levels were normalized by com-
parison with GAPDH. Gene-specific primer pairs are pre-
sented in Table 1.
Capillary-like structure formation assay
Cells (2 × 104) were seeded on 96-well flat-bottom plates
coated with 30 μl Matrigel (Lifetechnologies) and cultured
in EGM-2 medium. Eighteen hours after incubation,
capillary-like structures were observed under an Axiovert
microscope (Carl-Zeiss, Oberkochen, Germany).
Flow cytometry and cell sorting
Cells were detached using TrypLe (Lifetechnologies), re-
suspended in PBS-containing 2 % FBS and 2 mM EDTA,
and then stained with fluorochrome-leveled mAbs for
20 min on ice. Living cells were identified by 7-AAD
exclusion and then analyzed for cell surface marker
expression using a FACSCalibur flow cytometer (BD
Bioscience). Fifteen and 25 days after lentivirus gene
transduction, cells were labeled as already described and
sorted using a FACSJazz (BD Bioscience). Collected
events were analyzed using FACS software.
VEGF measurement
The supernatant was collected after changing with fresh
medium for 48 h and stored at −20 °C until analysis.
VEGF measurement was performed using a human VEGF
ELISA kit (Abcam, Cambridge, UK).
Statistical analysis
Statistical analyses of all endpoints were performed
using the two-sided Student’s t test or one-way analysis
of variance. All data are presented as mean ± SD. p < 0.05
was considered statistically significant. Data were analyzed
with Prism 6.0 software.
Results
Isolation and culture of HFs
Dermal HFs were isolated by culture expansion from
dermal tissues. HFs appeared in culture at day 4 with a
spindle shape (Fig. 1a). At day 14, the fibroblasts reached
70–80 % confluency (Fig. 1b). The cultures were subcul-
tured to expand the fibroblast population and eliminate
keratinocyte contamination. At the fifth passage, the
fibroblasts were homogeneous in shape under a micro-
scope (Fig. 1c). These cells were stored in liquid nitrogen
for further experiments.
ETV2 transduced fibroblasts contain CD31-positive cells
To establish EPCs, HFs were transduced with ETV2
virus for 14 days, after which cells were examined for
the EPC phenotype. Using an inverted microscope, we
observed some clusters of fibroblasts with four to five
cells with a round shape (Fig. 2e). We also examined the
morphology of cells in both hypoxia and normoxia con-
ditions, and observed more clusters in the hypoxia group
(Fig. 2i) compared with the normoxia group.
To confirm these round cells as EPCs, we evaluated
CD31 expression. The results showed that round cells in
both the normoxia and hypoxia groups were positive for
Table 1 Gene-specific primers used for quantitative RT-PCR
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CD31 (Fig. 2e–h and Fig. 2i–l), while spindle-like cells
were negative for CD31. Fibroblasts (100 %) were nega-
tive for CD31 expression (Fig. 2a–d), while 100 % of
HUVECs, used as a positive control, were positive for
CD31 expression (Fig. 2m–p).
ETV2 combined with hypoxia improved reprogramming
efficacy compared with ETV2 transduction alone
To compare the effects of normoxia and hypoxia on the
efficacy of reprogramming fibroblasts to EPCs, samples
transduced for 14 days were analyzed for CD31 expres-
sion by flow cytometry. The results showed that ETV2-
transduced fibroblasts under both normoxia and hypoxia
conditions contained a small population of CD31-
positive cells. However, in the hypoxia group the repro-
gramming efficacy toward EPCs significantly increased
to 7.52 ± 2.31 %, compared with 1.21 ± 0.61 % in the
normoxia group (p > 0.05). We did not observe any
CD31-positive cells in the negative control (fibroblasts)
(Fig. 3a), and confirmed 100 % of HUVECs positive for
CD31 expression. Similarly, ETV2 virally transduced
fibroblast samples showed a significant increase in the cell
population positive for VEGFR2, and an increase in cells
positive for both CD31 and VEGFR2 (Fig. 3b, c).
Fig. 1 Isolation and culture of HFs from human skin. (a) Skin tissue was cultured to isolate the fibroblasts. These fibroblasts were subcultured to
the second passage (b) and fifth passage (c) for further use
Fig. 2 Expression of CD31. HFs did not express the CD31 marker (a–d). Some cells expressed CD31 in normoxia conditions and transduction with
ETV2 (e–h) and in transduction with ETV2 and hypoxia conditions (i–l). Almost all HUVECs expressed CD31 (m–p). HUVEC human umbilical vein
endothelial cell
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To evaluate the induced EPCs in both normoxia and
hypoxia compared with HUVECs, the CD31-positive pop-
ulations in both normoxia and hypoxia were sorted using
a cell sorter. Induced EPCs were enriched to 97.11 ±
5.17 % and 96.32 ± 4.32 % in normoxia and hypoxia sam-
ples at the second sorting times, respectively (Fig. 3d, e).
Sorted induced EPCs were stained with markers for
EPCs and expressions were assessed by flow cytometry
(Fig. 4). HFs (negative control) were negative for CD31,
VEGFR2, CD34, Tie2, and CD45, were slightly positive
for NRP1 (11.43 %), and were strongly positive for
CXCR4 (95.43 %). Sorted induced EPCs under hypoxia
conditions were positive for CD31 (100 %), VEGFR2
(95.31 %), NRP1 (88.89 %), and CXCR4 (100 %), and
were negative for CD34, Tie2, and CD45. Sorted induced
EPCs in normoxia conditions were also positive for
CD31 (100 %), VEGFR2 (40.12 %), NRP1 (95.19 %), and
CXCR4 (100 %), and were negative for CD34, Tie2, and
CD45. The marker profile of induced EPCs in both
normoxia and hypoxia conditions were similar to the
HUVEC positive control, with positive expression of
CD31 (100 %), VEGFR2 (60.67 %), NRP1 (100 %), and
CXCR4 (100 %), and negative expression for CD34, Tie2,
and CD45. The marker profiles were similar between
normoxia-induced EPCs and hypoxia-induced EPCs.
Similar gene expression patterns in induced fibroblasts
and HUVECs
To confirm whether induced EPCs were similar to nor-
mal EPCs/endothelial cells (with HUVECs as control),
several endothelial cell-related genes were evaluated in
induced EPCs in both normoxia and hypoxia conditions
compared with HUVECs. The results showed that al-
most all endothelial cell-related genes, including NRP2,
NR2F2, EPHB4, JAG1, EFNB2, HEY1, PROX2, and
SOX18, were expressed in induced EPCs. These genes
were expressed at low levels in HFs, and were strongly
expressed in HUVECs. Generally, endothelial cell-related
genes significantly increased in ETV2 transduced fibro-
blasts in both hypoxia and normoxia. However, expres-
sion of these genes in transduced cells was lower than in
HUVECs. There were some differences in expression of
some genes between induced EPCs in hypoxia and
normoxia conditions, but these differences were not
Fig. 3 Hypoxia improves the reprogramming of ETV2 of fibroblasts into EPCs. HFs were negative for both CD31 and VEGFR2 (a), while ETV2
transduced cells contained a small population of CD31+VEGFR2+/− (b). In the hypoxia condition, ETV2 transduced fibroblasts significantly
increased to form CD31+VEGFR2+ cells (c). To evaluate some cell characteristics from two cell populations, all CD31+ cells in the groups of
normoxia and transduction with ETV2 (d) and of hypoxia and transduction with ETV2 (e) were sorted
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statistically significant (p > 0.05), except for the EFNB2
gene (Fig. 5).
Formation of capillary-like networks on Matrigel
Induced EPCs were assessed for in-vitro capillary forma-
tion in Matrigel. As shown in Fig. 6, induced EPCs in both
normoxia and hypoxia conditions could form capillaries
similar to HUVECs, while HFs could not form. There was
no difference in capillary formation of induced EPCs in
normoxia and hypoxia conditions (Fig. 6).
VEGF and increased efficacy of reprogramming
We next examined the levels of VEGF in medium from
cells cultured in normoxia and hypoxia conditions. The
VEGF concentration was significantly increased in the
hypoxia culture-derived supernatant compared with the
normoxia culture-derived supernatant (5.51 ± 1.43 pg/ml
in hypoxia culture vs 1.52 ± 0.41 pg/ml in normoxia
culture) (p < 0.05).
We then examined the effects of modulating VEGF
concentrations under both conditions. First, the medium
in cells cultured under normoxia conditions was supple-
mented with VEGF (10 ng/ml) and then fibroblasts
were virally transduced with ETV2. Addition of VEGF
increased the reprogramming efficacy under normoxia
conditions from 1.42 ± 0.32 % of CD31-positive cells
in medium without VEGF (Figs. 7b and 8a–e) to 9.56
± 3.12 % of CD31-positive cells in medium with VEGF
Fig. 4 ETV2 transduced fibroblasts expressed EPC phenotypes. The transduced cells from both groups (ETV2 + normoxia and ETV2 + hypoxia)
exhibited some similar characteristics. They were positive for CD31, CXCR4, and NRP1. VEGFR2 expression was different in the two groups; in hypoxia
conditions the transduced cells strongly expressed this marker compared with normoxia conditions. Generally, ETV2 transduced cells in both normoxia
and hypoxia conditions exhibited phenotypes similar to HUVECs and different to fibroblasts. HUVEC human umbilical vein endothelial cell
Fig. 5 Expression of some genes in induced cells compared with
HUVECs. (a) NRP2, NR2F2, EPHB4, JAG1, and SOX18. (b) EFNB2, HEY1,
and PROX2. Generally almost endothelial cell-related genes significantly
increased in ETV2 transduced fibroblasts in both hypoxia and
normoxia. However, expression of these genes in transduced cells was
lower than in HUVECs. HUVEC human umbilical vein endothelial cell
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(Figs. 7c and 8f–j) compared with 0 % in fibroblasts
(Fig. 7a).
We next supplemented cells in hypoxia culture with
an anti-VEGF antibody and found that the reprogram-
ming efficacy was lower in anti-VEGF antibody-treated
hypoxic cells (2.14 ± 0.49 % CD31-positive cells, Figs. 7e
and 8k–o) compared with 5.54 ± 2.13 % CD31-positive
cells under hypoxia conditions (Figs. 7d and 8p–t).
Discussion
EPCs are considered an important cell source for vascu-
lar regeneration. However, isolation of EPCs from umbil-
ical cord blood, peripheral blood, and bone marrow has
not been successful owing to low numbers of EPCs in
these blood sources. Many studies have therefore exam-
ined strategies to improve the proliferation and expan-
sion of these cells. Other groups have pursued the direct
reprogramming of fibroblasts into EPCs. Recent reports
using ETV2 transfection showed that HFs could be
directly reprogrammed into endothelial cells or EPCs.
However, these preliminary studies showed that repro-
gramming of fibroblasts to endothelial cells or EPCs was
low. In this study, we successfully increased the repro-
gramming efficacy by hypoxia treatment.
ETV2 overexpression can cause the differentiation
of stem cells into endothelial cells. ETV2 is a master
gene that regulates various signaling pathways and
functions as an essential regulator for vasculogenesis
and hematopoiesis. ETV2 interacts with GATA2 in
endothelial and hematopoietic cells in the early stages
of embryogenesis. ETV2 and GATA2 bind to the pro-
moter of SPI1 and regulate its expression during
embryogenesis [43]. Therefore, in a recent study, Liu
et al. [51] could induce the hematopoietic and endo-
thelial cell program by overexpression of ETV2. The
authors showed that ETV2 could activate ETS genes,
resulting in initiation of the hematopoietic and endo-
thelial cell program. ETV2 has also been suggested as
a direct regulator of Sox7 [52]. Overexpression of
ETV2 in embryonic bodies resulted in enhanced and
increased angiogenesis, while knockdown of ETV2 by
shRNA significantly decreased angiogenesis [52]. ETV2
also regulates cardiac development [44], and a recent
study showed that ETV2 is also an essential factor for
vascular regeneration [45].
Elcheva et al. [53] successfully induced human pluri-
potent stem cells into hematoendothelial cells using
ETV2 transfection. Lindgren et al. [54] confirmed that
addition of exogenous ETV2 to human ESCs significantly
increased the number of cells expressing angioblast
genes. Etv2 alone is required for early vasculogenesis,
whereas Etv2 and Fli1b function redundantly during
Fig. 6 Capillary-like network on Matrigel by cells in groups. (a) HFs could not form the capillary-like network. (b) ETV2 transduced HFs in both nor-
moxia and hypoxia, successfully forming the capillary-like network (c) similar to HUVECs (d). HUVEC human umbilical vein endothelial cell
Fig. 7 CD31-positive cells analyzed by flow cytometry. As a negative control, HFs did not contain the CD31+ population (a). In the normoxia
condition, ETV2 transduced HFs contained a small CD31+ cell population (b). A larger population of CD31+ cells was present in ETV2 transduced
HFs under hypoxia (d), similar to the ETV2 transduced HFs under normoxia supplemented with VEGF (c). The percentage of CD31+ cells significantly
decreased in the ETV2 transduced HFs under hypoxia supplemented with anti-VEGF monoclonal antibody (e). VEGF vascular endothelial growth factor.
SSC Side Scatter
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late vasculogenesis and early embryonic angiogenesis
[55]. With the important role of ETV2 in both early
embryogenesis and vascular regeneration in the adult,
some initial studies could only use this factor to dir-
ect reprogramming of fibroblasts to endothelial cells.
Our results showed that after 14 days of reprogramming
with ETV2 transduction, HFs exhibited specific properties
of EPCs/endothelial cells, including strong expression of
CD31, VEGFR2, and NRP1. Induced EPCs also expressed
a gene profile similar to that in HUVECs. More import-
antly, these sorted induced EPCs with CD31 expression
could form capillary-like networks in vitro in Matrigel.
Together these phenotypes confirmed that ETV2 trans-
duced fibroblasts were functional EPCs.
Our study also showed that hypoxia markedly affected
reprogramming efficacy. Hypoxia treatment during the
reprogramming procedure increased the number of cells
converted to EPCs. However, hypoxia in combination
with ETV2 transfection did not affect the induced EPC
phenotypes.
We next considered the mechanisms by which hypoxia
could increase the reprogramming of ETV2 transduced
fibroblasts into EPCs. We observed a marked difference
in VEGF concentration in supernatants from hypoxia
and normoxia cultured cells, suggesting that VEGF may
be the main factor contributing to the increased efficacy
of cell reprogramming. In fact, our results showed that
HFs produced over 3-fold more VEGF under hypoxia
conditions compared with cells in the normoxia condi-
tion, which is similar to previously published studies
[56–61]. This observation also was recorded in some
stem cells that could increase the production of VEGF
under hypoxia [62–64].
To determine whether VEGF is a main factor affecting
reprogramming efficacy, we supplemented VEGF in the
culture medium under normoxia conditions and found
that reprogramming efficacy was increased compared
with cells without additional VEGF. Moreover, repro-
gramming efficacy in hypoxia conditions decreased when
cells were supplemented with anti-VEGF monoclonal
antibody. We thus concluded that VEGF is the main fac-
tor involved in the direct reprogramming of fibroblasts
into EPCs by ETV2 transduction.
Conclusion
EPCs are important cells for angiogenesis and ischemia-
related disease treatments. However, EPCs are rare cells in
peripheral blood, bone marrow, and umbilical cord blood.
Here, we showed that single-factor ETV2 transduction
was a simple approach to produce EPCs from fibroblasts.
Fig. 8 CD31 expression in ETV2 transduced fibroblasts. ETV2 transduction under the hypoxia condition (p–t) significantly increased CD31+ cells
compared with normoxia (a–e), but significantly decreased if the medium was supplemented with anti-VEGF monoclonal antibodies (k–o). In the
normoxia condition, adding VEGF to the medium culture of ETV2 transduced cells could significantly increase the CD31+ cells (f–j). VEGF vascular
endothelial growth factor
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Notably, ETV2 transduction in combination with hypoxia
treatment resulted in increased efficacy of reprogramming
from fibroblasts to EPCs. These induced EPCs exhibited
EPC phenotypes and could form capillary networks in
vitro, similar to human umbilical endothelial cells. These
findings suggest a simple strategy to increase the repro-
gramming efficacy from fibroblasts to EPCs.
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